Clinical relevance of collagen protein degradation markers c3m and c4m in the serum of breast cancer patients treated with neoadjuvant therapy in the geparquinto trial

HIGHLIGHTS

• who: Malgorzata Banys-Paluchowski and collaborators from the Department of Gynecology and Obstetrics, Asklepios Klinik Barmbek, Hamburg, Germany Department of Gynecology, University of Hamburg-Eppendorf, Hamburg, Germany have published the research work: Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial, in the Journal: (JOURNAL) of 12/04/2007
• what: The aim of this study was to evaluate the potential clinical relevance of the serum collagen degradation markers (CDM) C3M and C4M during neoadjuvant chemotherapy for breast cancer. All . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.